Chr. Hansen's 2’-FL HMO receives approval for infant formula in ANZ
Food Standards Australia New Zealand (FSANZ) has approved Chr. Hansen’s 2’-FL human milk oligosaccharide (HMO) to be used in infant formulas in Australia and New Zealand. 2'-FL HMO is the most abundant and most studied human oligosaccharide in breast milk, used in infant formula around the world since 2016.
The addition of the 2’-FL HMO ingredient in infant formula is designed to produce milk closer in composition to human breast milk.
“Breastfeeding is the best way to ensure infant health and recommended by WHO. At Chr. Hansen, we further aim to support the healthy development of infants that cannot be breastfed by providing HMOs as an ingredient for infant formula,” said Dr Katja Parschat, head of Research & Development at Chr. Hansen HMO.
“The latest research shows that HMOs contribute to health benefits, such as supporting the immune system and healthy brain development. Also, HMOs are indicated to support gut maturation and resilience, as well as promotion of a balanced gut microbiome. We are happy to be able to offer our solutions to customers in Australia and New Zealand now.”
SMC upgrades chillers to meet new refrigerant regulations
Many of SMC Corporation's thermo-chillers now answer to the call for a more environmentally...
CSIRO's new data resource for verifying Australia's food fingerprint
CSIRO has today launched a national resource of Australia's isotopic data, which can be used...
Eel appeal: Japanese consumers willing to try cultured eel
A recent survey reveals an openness among Japanese consumers towards eel alternatives, including...
